Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,200

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

2018 Update of the EULAR recommendations for the management of large vessel vasculitis

Open access
Hellmich, Bernhard, Agueda, Ana, Monti, Sara, Buttgereit, Frank, de Boysson, Hubert, Brouwer, Elisabeth, Cassie, Rebecca, Cid, Maria C, Dasgupta, Bhaskar, Dejaco, Christian, Hatemi, Gulen, Hollinger, Nicole, Mahr, Alfred, Mollan, Susan P, Mukhtyar, Chetan, Ponte, Cristina, Salvarani, Carlo, Sivakumar, Rajappa, Tian, Xinping, Tomasson, Gunnar, Turesson, Carl, Schmidt, Wolfgang, Villiger, Peter M, Watts, Richard, Young, Chris, Luqmani, Raashid Ahmed · 2020 · Annals of the Rheumatic Diseases

Abstract

Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. Methods Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. Results Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. Conclusions We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2019-215672

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 1,200

Metadata

Authors
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., Hatemi, G., Hollinger, N., Mahr, A., Mollan, S. P., Mukhtyar, C., Ponte, C., Salvarani, C., Sivakumar, R., Tian, X., Tomasson, G., Turesson, C., Schmidt, W., Villiger, P. M., Watts, R., Young, C., & Luqmani, R. A.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2020-01
Volume
79
Issue
1
Pages
19-30
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2954943567
Cited by
1,200
References
80
FWCI
82.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. https://app.cochat.ai/papers/10.1136/annrheumdis-2019-215672
The paper
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., Hatemi, G., Hollinger, N., Mahr, A., Mollan, S. P., Mukhtyar, C., Ponte, C., Salvarani, C., Sivakumar, R., Tian, X., . . . Luqmani, R. A. (2020). 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2019-215672

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.